The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Animal Parasiticides Market will exceed $6.5bn by 2024 25 April 2018 Animal Health The competitive hierarchy of animal parasiticides market recently witnessed one of the most lucrative partnerships of the year, as Merial signed an alliance with the German pharmaceutical company, Boehringer Ingelheim. Post the successful merger, the latter has apparently decided to expand the production capacity of its animal health manufacturing facility at St. Joseph, which would undoubtedly help the company strengthen its position in animal parasiticides industry. Considering the huge demand for parasiticides and pet products, it has been observed that many other companies have also been attempting to ramp up their product portfolio. Recently, Elanco Companion Animal Health launched a massive product range of parasiticides, designed for preventing heartworm disease, whipworm infection, and flea infestations in puppies and dogs. The growing prevalence of zoonotic diseases in the animals is thus, likely to boost animal parasiticides industry share over the years ahead. As per estimates though, in 2016, animal parasiticides market was worth USD 5 billion. Regulatory bodies such as the U.S. Food and Drugs Administration (FDA), it has been observed, are also taking initiatives to promote the manufacturing of eco-friendly products. The U.S. Environmental Protection Agency (EPA) for instance, has instituted the President Green Chemistry Challenge Award to motivate manufacturers for developing environment friendly products, the honor of which would undoubtedly prove to be a major driving force for companies in animal parasiticides industry to focus on safer design and latest technology facilities. Driven by a stringent regulatory framework and the early adoption of neoteric products, North America animal parasiticides market is expected to chart out a lucrative growth path in the ensuing years. In fact, as per the estimates, in 2016, North America animal parasiticides industry covered 25% of the overall share, pertaining to the rise in pet population and animal farming. �As per estimates though, in 2016, animal parasiticides market was worth USD 5 billion� In the United States, the FDA is responsible for drafting the regulations for limiting the deployment of pesticides in animal-derived products. The association recommended that pet food needs to be hygienic and should not contain any deleterious residue, which may be injurious to animal health. In accordance with the same, the FDA has enforced certain norms for parasiticide manufacturers, which would have a commendable impact on the product landscape of animal parasiticides market. In addition, the U.S. Department of Agriculture has also undertaken the responsibility for regulating veterinary biologics, prominently used for supplementing and enhancing animal immune system, to enhance their safety, effectiveness, purity, and potency. The initiatives undertaken by regulatory bodies would thus, le
Beware potential investors
Beware potential share buyers
Good message i need a bit of cheering up. Well we know the problems red mites cause and yes poultry is a good size market. What worries me is the amount of working capital Tyratech have let's hope they don't run out of money
http://www.thepoultrysite.com/articles/3751/red-mite-an-underestimated-problem-in-poultry-production/ bearing in mind Tyratech field trials for control of red mites in poultry started last month (link below for anyone not seen it): http://tyratech.com/preparing-for-poultry-red-mite-field-trials/ Could this be one of the blockbusters? No real effective control of red mite with parasiticides, very easily transferred from flock to flock and linked with transmission of other diseases and estimated to cost the industry 130 million euros in Europe alone. Ivy Spivey - what's your take on this?
Thanks for your words of encouragement
No problem. Not quite. They still have a fair few million dollars in the bank after the sale of Vamousse. So still some time.
it's contract or bust
Such small volumes that any buys or sells moves the sp. Three buys on Friday. Not massive, but enough to raise the sp. Would be nice to hear something soon from the company. Any substantial contract would send this northwards very fast.
Up nearly 20% on Friday anyone know the accurate reason why hopefully contract related
The webpage is very active with what is going on. If one of these products is successful in the USA and Europe this price will soar. http://www.tyratech.com/preparing-for-poultry-red-mite-field-trials/
I think contracts are what people are waiting to hear about � don't know about earnings, anything would be good, seems to me most of previous earnings came from Vamousse.! I just did a quick tally of current value: given they have 161,587,641 common shares currently and the price is around 2,35 (pence) that gives a value of just under 3.8 million (I think!) do people agree? This seems low to me, especially if their potential looks like coming to fruition. Any smidgen of good news and I'm hoping this will zoom north.
and/or other Tyratech contributors, what revenues would seem realistic for TYRU to generate through 2018. Based on previous years,a trading update would appear due and this might provide some guidance. Should the T.U. be positive then I believe those who did not accept the tender will be vindicated and rewarded.
Thanks Jesk I had not seen that posted on their website, it just needs backing up with a nice big sales contract !
Let's hope for some concrete good news soon. http://www.tyratech.com/the-futures-bright/
This time last year we had a trading update giving us details that a strategic review was about to commence and ultermatly change the direction of Tyratechs business focus.A lot of water under the bridge since then and now hopefully time to get some real idea of what developments have been happening in the meantime .
I agree with points you make. If the product(s) are as good as they seem to be I think it makes sense to hang on in and wait for good news which I believe will come.
TheTid & JESK - Thanks for the heads up, both. If you compare the presentation they did for the poultry industry in 2016 it was to North American farmers only. So going international shows the increasing scale of their ambitions. One of the things that impresses me most about Bruno is how many big companies - in the case of PureScience, MWI - he has promoting the PureScience range. This cuts down big time on cost of A&M - the big problem faced by the now disposed human health products. Can't help feeling big contract news not far off.
http://www.tyratech.com/purescience-progress/ Hope the next RNS shows good progress being made with the PureScience range.
whoops, freudian slip perhaps. Not tasing but trading update.
Saw on their website they were at a poultry trade event on Friday selling their wares hopefully. Maybe some news on this front?
Trading update came on the 9th Feb last year so we should be closer to knowing what has been happening behind the scenes on the animal health side of the business. Been a bit quiet on this board lately, I just hope you lot have not lost the faith.If the poultry mite dust is as good as the initial reviews this may be one of the blockbusters Bruno was talking about . Fingers crossed !
So far so good I would say: I tendered a few but kept most of my holding. I was concerned that it might just dive after the tender and the sale of Vamousse. I'm hoping the fact that the share price has held is a good sign? The tendered shares are officially wiped on the 8th (I think they said) so fingers crossed.
Interesting - I tendered to a break even position. Will be watching and but some more as this company develops. No doubt for more than 3p!
Good morning,Ivy. Yes, some very significant information for me that, re the Board. I just wish they would post RNSs on TYRU, too.